IMA Advisory Services Inc. Sells 832 Shares of Zoetis Inc. $ZTS

IMA Advisory Services Inc. reduced its position in Zoetis Inc. (NYSE:ZTS) by 8.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,101 shares of the company’s stock after selling 832 shares during the quarter. IMA Advisory Services Inc.’s holdings in Zoetis were worth $1,419,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nova Wealth Management Inc. acquired a new position in Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank acquired a new position in shares of Zoetis during the 1st quarter worth $29,000. REAP Financial Group LLC lifted its position in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC boosted its stake in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $119.88 on Tuesday. The stock has a market cap of $52.83 billion, a price-to-earnings ratio of 20.63, a P/E/G ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a twelve month low of $117.26 and a twelve month high of $181.85. The company’s fifty day moving average is $143.48 and its 200 day moving average is $152.40. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the business earned $1.58 EPS. The business’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is presently 33.67%.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. UBS Group dropped their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Morgan Stanley dropped their price objective on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday. Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $182.50.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.